Mylan Looks To Extend Intellectual Property Protection For Beta Blocker Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
The company anticipates protection beyond the compound patent, which expires in 2020. The NDA for the antihypertensive was filed April 30.